Ivosidenib

Ivosidenib is a tertiary carboxamide formed by the condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is FDA-approved for treating acute myeloid leukemia (AML) in patients with isocitrate dehydrogenase-1 (IDH1) mutations. It functions as an antineoplastic agent and inhibitor of EC 1.1.1.42 (isocitrate dehydrogenase). It belongs to the classes of monochlorobenzenes, cyanopyridines, pyrrolidin-2-ones, organofluorine compounds, tertiary carboxamides, and secondary carboxamides.